Th1 epitope selection for clinically effective cancer vaccines.
New cancer immunotherapies mark progress in our understanding of tumor biology and harnessing the immune system's management of self. However, protein- and peptide-based vaccines are not yet consistently efficacious. Recent work uncovers principles governing the genesis of T helper type-restrictive immunity to self-antigens elicited by vaccine epitopes, enabling vaccines to skew the balance from tolerogenic Type II (Th2) to inflammatory Type I (Th1) T cells, and invigorating this cancer immunotherapeutic approach.
Tumor Vaccine Group; Center for Translational Medicine in Women's Health; University of Washington ; Seattle, WA USA.
Mary L
ML
Disis
Tumor Vaccine Group; Center for Translational Medicine in Women's Health; University of Washington ; Seattle, WA USA.
William C
WC
Watt
Tumor Vaccine Group; Center for Translational Medicine in Women's Health; University of Washington ; Seattle, WA USA.
Denise L
DL
Cecil
Helper T-cells; IGFBP-2; Th1; Th2; epitope